

An Experimental and Theoretical Approach to Relativistic Oncological Effectiveness Studies Using Proton Beam from Ion Accelerator

Alireza Heidari^{1,2,3,4*}

¹California South University, 14731 Comet St. Irvine, CA 92604, USA

²BioSpectroscopy Core Research Laboratory, California South University, 14731 Comet St. Irvine, CA 92604, USA

³Cancer Research Institute (CRI), California South University, 14731 Comet St. Irvine, CA 92604, USA

⁴American International Standards Institute, Irvine, CA 3800, USA

***Correspondence:** Faculty of Chemistry. Alireza Heidari, California South University, 14731 Comet St. Irvine, CA 92604, USA

Received Date: Aug 02, 2022 / **Accepted Date:** Sep 15, 2022 / **Published Date:** Sep 20, 2022

Abstract

Proton openness to radiation has been created to (achieve or acquire with exertion) the medication-based advantage of further developed 3D-portion dissemination, with (connected with the body capability of living things) properties practically equivalent to X-beams.

Keywords

Hadrontherapy, Radiotherapy, Cancer, Treatment, Cure, Tumors, Oncology, Particle Therapy

Letter

Proton openness to radiation has been created to (achieve or acquire with exertion) the medication-based advantage of further developed 3D-portion dissemination, with (connected with the body capability of living things) properties practically equivalent to X-beams. Neutron openness to radiation, however significantly less 3D-conformal than proton therapy, has been created to exploit expanded relative biologic adequacy (RBE). Openness to radiation with hadrons heavier than protons (for example carbon and neon particles) shows the (like nothing else on the planet) mix of further developed 3D-portion conveyance and expanded RBE. The synchrotron innovation is rapidly creating to work on the (squandering very little while working or delivering something) of conveying these heavier hadrons (connected with medication and science), yet significant issues stay (connected with/checking out/contemplating) advancement of portion and fractionation limits/rules in the treatment of various histopathologists situated in various pieces of/measures of the (body structure). Numerous research center creature and in vitro cell studies, and some medication based examinations, have been performed to empower better comprehension of how to (change to improve/change to fit new circumstances) portion fractionation determination to work on the medicinally supportive proportion of growth cell kill to (normal/generally and standard/solid)-tissue injury. This paper features the worked on restoratively accommodating (conceivable significance or power) and associated dangers of treatment with these heavier hadrons [1-30].

Acknowledgement

This study was supported by the Cancer Research Institute (CRI) Project of Scientific Instrument and Equipment Development, the National Natural Science Foundation of the United States, the International Joint BioSpectroscopy Core Research Laboratory (BCRL) Program supported by the California South University (CSU), and the Key project supported

References

1. Heidari A, Brown C. Study of Composition and Morphology of Cadmium Oxide (CdO) [Nanoparticles](#) for Eliminating [Cancer](#) Cells. *J Nanomed Res.* 2015; 2(5)20:2015.
2. Heidari A, Brown C. Study of Surface Morphological, Phytochemical and Structural Characteristics of Rhodium (III) Oxide (Rh₂O₃) [Nanoparticles](#). *Int J Pharmacol Phytoche Ethnomed.* 2015;1(1):15-19.
3. Heidari A. An Experimental Biospectroscopic Study on Seminal Plasma in Determination of Semen Quality for Evaluation of Male Infertility. *Int J Adv Technol.* 2016;7: e007.
4. Heidari A. Extraction and Preconcentration of N-Tolyl-Sulfonyl-Phosphoramid-Saeure-Dichlorid as an Anti-Cancer Drug from Plants: A Pharmacognosy Study. *J Pharmacogn Nat Prod.* 2016;2: e103.
5. Heidari A. A Thermodynamic Study on Hydration and Dehydration of [DNA](#) and RNA-Amphiphile Complexes. *J Bioeng Biomed Sci.* 2016;S:006.
6. Heidari A. Computational Studies on Molecular Structures and Carbonyl and Ketene Groups' Effects of Singlet and Triplet Energies of Azidoketene O=C=CH–NNN and Isocyanatoketene O=C=CH–N=C=O. *J Appl Computat Math.*2016;5:e142.
7. Heidari A. Study of Irradiations to Enhance the Induces the Dissociation of Hydrogen Bonds between Peptide Chains and Transition from Helix Structure to Random Coil Structure Using ATR–FTIR, Raman and ¹HNMR Spectroscopies. *J Biomol Res Ther.* 2016;5:e146.
8. Heidari A. Future Prospects of Point Fluorescence Spectroscopy, Fluorescence Imaging and Fluorescence Endoscopy in [Photodynamic Therapy](#) (PDT) for [Cancer](#) Cells. *J Bioanal Biomed.* 2016;8: e135.
9. Heidari A. A Bio-Spectroscopic Study of [DNA](#) Density and Color Role as Determining [Factor](#) for Absorbed Irradiation in [Cancer](#) Cells. *Adv [Cancer](#) Prev.* 2016;1: e102.
10. Heidari A Manufacturing Process of Solar [Cells](#) Using Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh₂O₃) [Nanoparticles](#). *J Biotechnol Biomater.*2016;6: e125.
11. Heidari A. A Novel Experimental and Computational Approach to Photobiosimulation of Telomeric DNA/RNA: A Biospectroscopic and Photobiological Study. *J Res Development* 2016;4:144.
12. Heidari A. Biochemical and Pharmacodynamical Study of Microporous Molecularly Imprinted Polymer Selective for Vancomycin, Teicoplanin, Oritavancin, Telavancin and Dalbavancin Binding. *Biochem Physiol.* 2016;5:e146.
13. Heidari A. Anti-Cancer Effect of UV Irradiation at Presence of Cadmium Oxide (CdO) [Nanoparticles](#) on [DNA](#) of [Cancer](#) Cells: A [Photodynamic Therapy](#) Study. *Arch [Cancer](#) Res.* 2016;4:1.
14. Heidari A. Biospectroscopic Study on Multi–Component Reactions (MCRs) in Two A–Type and B–Type Conformations of [Nucleic Acids](#) to Determine Ligand Binding Modes, Binding Constant and Stability of [Nucleic Acids](#) in Cadmium Oxide (CdO) [Nanoparticles](#)–[Nucleic Acids](#) Complexes as Anti–[Cancer](#) Drugs. *Arch [Cancer](#) Res.* 2016;4:2.
15. Heidari A. Simulation of Temperature Distribution of DNA/RNA of Human [Cancer Cells](#) Using Time–Dependent Bio–Heat Equation and Nd: YAG Lasers. *Arch [Cancer](#) Res.* 2016;4:2.
16. Heidari A. Quantitative Structure–Activity [Relationship](#) (QSAR) Approximation for Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh₂O₃) [Nanoparticles](#) as Anti-Cancer [Drugs](#) for the Catalytic Formation of Proviral [DNA](#) from Viral [RNA](#) Using Multiple Linear and Non-Linear Correlation Approach. *Ann Clin Lab Res.* 2016;4:1.
17. Heidari A. Biomedical Study of [Cancer Cells](#) [DNA](#) Therapy Using Laser Irradiations at Presence of Intelligent [Nanoparticles](#). *J Biomedical Sci.* 2016;5:2.
18. Heidari A. Measurement the Amount of Vitamin D2 (Ergocalciferol), Vitamin D3 (Cholecalciferol) and Absorbable Calcium (Ca²⁺), Iron (II) (Fe²⁺), Magnesium (Mg²⁺), Phosphate (PO⁴⁻) and Zinc (Zn²⁺) in Apricot Using High–Performance Liquid [Chromatography](#) (HPLC) and Spectroscopic Techniques. *J Biom Biostat.* 2016;7:292.
19. Heidari A. Spectroscopy and Quantum Mechanics of the Helium Dimer (He²⁺), Neon Dimer (Ne²⁺), Argon Dimer

- (Ar²⁺), Krypton Dimer (Kr²⁺), Xenon Dimer (Xe²⁺), Radon Dimer (Rn²⁺) and Ununoctium Dimer (Uuo²⁺) Molecular Cations. Chem Sci J. 2016;7: e112.
20. Heidari A. Human Toxicity [Photodynamic Therapy](#) Studies on DNA/RNA Complexes as a Promising New Sensitizer for the Treatment of Malignant Tumors Using Bio-Spectroscopic Techniques. J Drug Metab Toxicol. 2016;7: e129.
 21. Heidari A. Novel and Stable Modifications of Intelligent Cadmium Oxide (CdO) [Nanoparticles](#) as Anti-Cancer Drug in Formation of [Nucleic Acids](#) Complexes for Human [Cancer](#) Cells' Treatment. Biochem Pharmacol (Los Angel) 2016;5: 207.
 22. Heidari A. A Combined Computational and QM/MM Molecular Dynamics Study on Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a-BNNTs) and Hexagonal Boron Nitride Nanotubes (h-BNNTs) as Hydrogen Storage. Struct Chem Crystallogr Commun 2016;2.
 23. Heidari A. Pharmaceutical and [Analytical Chemistry](#) Study of Cadmium Oxide (CdO) [Nanoparticles](#) Synthesis Methods and Properties as Anti-Cancer Drug and Its Effect on Human [Cancer](#) Cells. Pharm Anal Chem Open Access. 2016;2:113.
 24. Heidari A. A Chemotherapeutic and Biospectroscopic [Investigation](#) of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh₂O₃) [Nanoparticles](#) as Anti-Cancer [Drugs](#) for [Cancer](#) Cells' Treatment", Chemo Open Access. 2016;5: e129.
 25. Heidari A. [Pharmacokinetics](#) and Experimental Therapeutic Study of [DNA](#) and Other [Biomolecules](#) Using Lasers: Advantages and Applications. J Pharmacokinet Exp Ther. 2016;1:e005.
 26. Heidari A. Determination of Ratio and Stability Constant of DNA/RNA in Human [Cancer Cells](#) and Cadmium Oxide (CdO) [Nanoparticles](#) Complexes Using Analytical Electrochemical and Spectroscopic Techniques. Insights Anal Electrochem 2016;2:1.
 27. Heidari A. Discriminate between Antibacterial and Non-Antibacterial [Drugs](#) Artificial Neutral Networks of a Multilayer Perceptron (MLP) Type Using a Set of Topological Descriptors. J Heavy Met Toxicity Dis. 2016;1: 2.
 28. Heidari A. Combined Theoretical and Computational Study of the Belousov-Zhabotinsky Chaotic Reaction and Curtius Rearrangement for Synthesis of Mechlorethamine, Cisplatin, Streptozotocin, Cyclophosphamide, Melphalan, Busulphan and BCNU as Anti-Cancer Drugs. Insights Med Phys. 2016;1:2.
 29. Heidari A. A Translational Biomedical Approach to Structural Arrangement of Amino Acids' Complexes: A Combined Theoretical and Computational Study. Transl Biomed. 2016;7:2.
 30. Heidari A. Ab Initio and Density Functional Theory (DFT) Studies of Dynamic [NMR](#) Shielding Tensors and Vibrational Frequencies of DNA/RNA and Cadmium Oxide (CdO) [Nanoparticles](#) Complexes in Human [Cancer](#) Cells. J Nanomedicine Biotherapeutic Discov 2016;6: e144.

Citation: Alireza Heidari. An Experimental and Theoretical Approach to Relativistic Oncological Effectiveness Studies Using Proton Beam from Ion Accelerator. Nanomed Nanosci Technol: Open Access 2022;2(3):1-5.

Copyright: © 2022 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.